Kanjinti and Mvasi Make ‘Solid Start’ In US

Amgen’s Global Biosimilars Annualizing At Around $700m

 
• By Aidan Fry

Launching its Kanjinti and Mvasi trastuzumab and bevacizumab biosimilars ‘at risk’ in July generated third-quarter sales of $81m for Amgen, contributing nearly half of global biosimilar turnover of $173m.

Sprinting
Amgen says its Kanjinti and Mvasi biosimilars have made a solid start in the US • Source: Shutterstock

More from Biosimilars

More from Products